We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
- Authors
Gillenwater, Heidi H; McCune, Jeannine S; Lindley, Celeste; Faucette, Stephanie; Shord, Stacy; Donahue, Angela; Socinski, Mark A; Stewart, Clinton F; Zamboni, William C; Kirstein, Mark N; Moore, Dominic
- Abstract
Topotecan is active in relapsed small cell lung cancer; thus, its addition to the standard carboplatin-etoposide regimen may improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients. Significant interpatient variability in the topotecan systemic exposure results when it is dosed based on body surface area (mg/m2). The purpose of this Phase I trial was to determine the maximally tolerated systemic exposure (MTSE) of topotecan in combination with carboplatin and etoposide.
- Publication
Cancer investigation, 2005, Vol 23, Issue 6, p511
- ISSN
0735-7907
- Publication type
Journal Article
- DOI
10.1080/07357900500201400